Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center

Click to increase image sizeClick to decrease image size

Acknowledgments

Chun Feng, M.A., Certified ASQ Six Sigma Black Belt, Sr. Informatics Analyst – Department of Pharmacy – Quality and Regulatory, Division of Pharmacy, University of Texas M.D. Anderson Cancer Center.

Author contributions

Alicia McGhie provided study design, collection and analysis of data and writing of the manuscript. Jenessa Lee provided study design, analyzed data, and review of the manuscript. Alessandra Ferrajoli provided study design, contributed patients, and reviewed and edited the manuscript. Adam J. DiPippo provided study design, collected and analyzed data, and reviewed and edited the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

A.F.: research funds: Astra-Zeneca and Beigene, advisory board: Janssen, Astra-Zeneca.